China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed ...

The GNPS Drug Library may be more broadly applicable for drug screening across diverse research disciplines, such as food and environmental monitoring.

ENIGMA-TRS 2 is a global, randomized, double-blind, placebo-controlled 12-week Phase III clinical study designed to enroll at least 400 patients; topline results are expected by Q4 2026Evenamide is a ...

Leon Bellan, associate professor of mechanical and biomedical engineering at Vanderbilt, and his team have developed a novel ...

Pulse Biosciences has partnered with The University of Texas MD Anderson Cancer Centre to investigate the use of the nPulse ...

Kuwait is set to enter a new phase in its fight against drugs with the implementation of the new drug law, effective December ...

AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS PRIOR ANY COMPLETE LOSS OF FUNCTION Significant improvement in ...

Argenica has used AI to identify an optimised sub-group of severe stroke patients for a follow-on phase IIb trial.

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Knee Osteoarthritis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering ...

ORLANDO -- Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve durable disease control in the second-line setting while stopping daily ...

Preliminary studies indicate that derivatives of verticillin A can kill certain types of glioma cells. MIT chemists have, for ...

Cancer Research UK's Centre for Drug Development is sponsoring and conducting the phase I/II clinical trial of ALETA-001, the lead agent in Aleta Biotherapeutics' portfolio. Additional clinical trial ...